AAV Podocyte-Targeted Gene Therapy for Monogenic Nephrotic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for monogenic forms of nephrotic syndrome, particularly steroid-resistant nephrotic syndrome (SRNS), are ineffective, leading to end-stage renal disease and high recurrence risk after renal transplant, with existing gene therapy approaches failing to target podocytes specifically and achieving long-term functional expression.
Innovation Solution
Adeno-associated virus (AAV) vector gene therapy using AAV serotypes 2/9, LK03, and 3B, combined with podocyte-specific promoters such as NPHS1 and NPHS2, to deliver NS-associated transgenes like podocin, targeting podocytes and minimizing off-target expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy approaches are used to deliver transgenes to the kidney, then gene delivery is attempted, but specific targeting of podocytes is not achieved and long-term functional expression is not obtained
Solution Approach 1:
The patent applies local quality by using podocyte-specific promoters (NPHS1 for nephrin, NPHS2 for podocin) that drive transgene expression specifically in podocytes rather than throughout the entire kidney. This ensures that the therapeutic gene product is produced only in the target cell type, achieving reliable specific targeting while maintaining long-term functional expression in the intended location.
Solution Approach 2:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver the transgenes to podocytes. These viral vectors serve as mediators that efficiently transport the therapeutic genetic material across the cell membrane and into the podocyte nucleus, enabling both specific targeting and sustained expression of the podocin or nephrin proteins.
2Productivity
If steroid therapy is used to treat nephrotic syndrome, then initial remission is achieved in 80% of patients, but relapse occurs and 10-15% develop steroid-resistant nephrotic syndrome
Solution Approach 1:
The patent extracts the underlying genetic defect causing monogenic nephrotic syndrome by delivering a functional copy of the defective gene (podocin or nephrin) via AAV vector. This addresses the root cause rather than merely suppressing symptoms with steroids, thereby achieving both initial remission and long-term treatment efficacy by correcting the genetic defect permanently.
Solution Approach 2:
The patent performs preliminary action by correcting the genetic defect before the disease progresses to end-stage renal disease. By early intervention with gene therapy in patients with monogenic forms of nephrotic syndrome, the therapeutic effect prevents relapse and steroid resistance from developing, ensuring long-term treatment efficacy.
3Quantity of substance
If viral vectors are used to deliver podocin-encoding nucleic acids, then gene transfer is attempted, but the complex kidney anatomy prevents specific transduction of podocytes
Solution Approach 1:
The patent applies local quality by combining AAV vectors with podocyte-specific promoters (NPHS1 or NPHS2) that ensure transgene expression occurs only in podocytes. This dual approach of using tissue-tropic viral vectors plus cell-type-specific promoters achieves both efficient gene transfer and precise spatial control of expression, overcoming the challenge of kidney's complex anatomy.
Solution Approach 2:
The patent changes the regulatory parameters of gene expression by using minimal promoters specific to podocyte genes (NPHS1 for nephrin, NPHS2 for podocin). These promoters are optimized to drive expression specifically in podocytes under physiological conditions, thereby achieving specific transduction and expression despite the complex kidney structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV vector therapy effectively reverses the nephrotic syndrome phenotype, reducing proteinuria, improving kidney function, and extending patient survival by specifically expressing functional podocin in podocytes, thereby correcting podocyte-associated kidney dysfunction.
Implementation Method 1
the AAV vector comprises: a NS-associated transgene; and minimal nephrin promoter NPHS1 or podocin promoter NPHS2
Implementation Method 2
adeno-associated virus (AAV) vector gene therapy using AAV serotypes 2/9, LK03, and 3B, combined with podocyte-specific promoters
Data Source
AI summary
The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHIS1 or podocin promoter NPHIS2.